NCT00773929View on ClinicalTrials.gov

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

April 30, 2010

Conditions
Solid Tumors
Interventions
DRUG

TAK-593

"Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety"

Trial Locations (1)

48201

Karmanos Cancer Institute, Detroit

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY